Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 1

Status

Completed 3Terminated 2

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3Breast 3Gastrointestinal 2Genitourinary 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 226Lung Neoplasms 78Neoplasms 37Mesothelioma 23Mesothelioma, Malignant 21Neoplasm Metastasis 20Breast Neoplasms 18Adenocarcinoma of Lung 18Head and Neck Neoplasms 13Colorectal Neoplasms 13Parkinson Disease 4, Autosomal Dominant Lewy Body 11Ovarian Neoplasms 11Carcinoma 8Uterine Cervical Neoplasms 6Non-Squamous Non-Small Cell Lung Cancer 6Adenocarcinoma, Bronchiolo-Alveolar 6Adenocarcinoma 6Unspecified Adult Solid Tumor, Protocol Specific 5Stomach Neoplasms 5Squamous Cell Carcinoma of Head and Neck 5Sarcoma 5Meningeal Carcinomatosis 5Brain Neoplasms 5Urinary Bladder Neoplasms 4Small Cell Lung Carcinoma 4Recurrence 4Prostatic Neoplasms 4Pancreatic Neoplasms 4Laryngeal Diseases 4Endometrial Neoplasms 4

Interventions

Carboplatin 41Paclitaxel 40pembrolizumab 38Cyclophosphamide 23Gemcitabine 22130-nm albumin-bound paclitaxel 21Doxorubicin 18Cisplatin 18Albumin-Bound Paclitaxel 18atezolizumab 16Taxes 15Capecitabine 13veliparib 10Nivolumab 9Docetaxel 9Bevacizumab 9olaparib 8liposomal doxorubicin 7Everolimus 7spartalizumab 6durvalumab 6Epirubicin 6trametinib 5pegfilgrastim 5eribulin 5Irinotecan 5Filgrastim 5iniparib 4binimetinib 4apatinib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Triple Negative Breast Neoplasms × Pemetrexed × Clear all
NCT03396445 2025-11-05

MK-5890-001

Merck Sharp & Dohme LLC

Phase 1 Completed
182 enrolled 36 charts
BreastThoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung, Triple Negative Breast Neoplasms

NCT03267316 2024-08-22

CANFOUR

Cantargia AB

Phase 1/2 Completed
167 enrolled
BreastGastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT02983045 2023-03-13

PIVOT-02

Nektar Therapeutics

Phase 1/2 Completed
557 enrolled 22 charts
BreastDermatologicGastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Melanoma, Neoplasm Metastasis, Stomach Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡